In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Xenetic Biosciences (XBIO – Research Report), with a price target of $4.00. The company's shares closed last Thursday at $0.62, close to its 52-week low of $0.45. According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of -34.8% and a 10.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. Currently, the analyst consensus on Xenetic Biosciences is a Moderate Buy with an average price target of $4.00.
https://www.tipranks.com/news/blurbs/xenetic-biosciences-xbio-gets-a-buy-rating-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Xenetic Biosciences (NASDAQ:XBIO)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Xenetic Biosciences Charts.
Xenetic Biosciences (NASDAQ:XBIO)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Xenetic Biosciences Charts.